(@ZeissJessy) on getquin

ZeissJessy

@ZeissJessy

3Wk·

$PTP (-0.21%) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (-2.63%) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (+2.24%)

Lantheus Holding $LNTH (+0.63%)

1 Comment

ThemenmitKopf@topicswithhead

3Wk

According to the venture probability valuation, the company value is around 100 to 150 million euros. I would actually like to get in, but statistically the share price is likely to fall even further. In addition, biotech has never really been in demand on the German stock exchange, which could lead to further setbacks. That really annoys me, because the share will easily slip below the 4-euro mark and I still don't know whether the bottom has been reached

•